Injective has signed a memorandum of understanding with BDACS to explore using KRW1, a won-backed stablecoin, as a settlement asset for tokenized markets and real-world assets on its network. The agreement, announced Tuesday, is non-binding and sets the stage for further technical and regulatory work before any integration goes live.
The MOU centers on whether KRW1 can serve as a reliable settlement layer for assets that trade on Injective, a layer-1 blockchain focused on finance. Neither firm disclosed a timeline for when a pilot might launch or how the stablecoin would be issued and redeemed.
What the MOU actually covers
The document is an exploratory agreement, not a commercial contract. It commits Injective and BDACS to study how KRW1 could be used to settle trades in tokenized markets and real-world assets on Injective's network. That includes examining the technical plumbing required to move the stablecoin across the chain and the compliance checks that would apply to issuers and holders.
KRW1 is described as a won-backed stablecoin, meaning its value is tied to the South Korean currency. The facts do not specify who issues KRW1, how reserves are held, or whether it has already launched. Those details would likely determine whether the stablecoin can be used in institutional settlement at all.
Why a won-backed asset matters for tokenized markets
Tokenized markets — where assets like bonds, funds, or commodities are represented on a blockchain — need a settlement asset that buyers and sellers both trust. Dollar-backed stablecoins dominate that role today. A won-backed alternative could appeal to Korean institutions that want to keep settlement in local currency rather than converting to dollars.
For Injective, the appeal is broader. The network has positioned itself as a venue for financial applications, and adding a fiat-backed stablecoin tied to a major Asian currency could attract issuers and traders who prefer not to use dollar stablecoins. The MOU doesn't guarantee that outcome, but it signals where the project is looking.
Regulatory questions remain unanswered
South Korea has been tightening its rules around stablecoins and digital assets, though the facts don't cite specific regulations. Any won-backed stablecoin used in settlement would likely need to satisfy local currency and securities laws, and the MOU doesn't say which regulator would oversee the arrangement.
BDACS, the counterparty, isn't described in the facts beyond its role in the agreement. It's unclear whether the firm is a custodian, an issuer, or a technology provider. Injective's announcement didn't name any executives or provide quotes from either side.
What happens next
The two parties will now work through the technical and legal questions the MOU raises. No deadline has been set for those discussions, and neither firm has said whether a pilot or production integration will follow. For now, the agreement is a signal of intent rather than a launch.
Injective users and tokenized-market participants won't see any immediate change. The next concrete step would be a technical specification or a regulatory filing, neither of which has been announced.
